TTC Oncology TO PRESENT AT BIOTECH SHOWCASE™ DIGITAL 2021

Chicago, IL -- January 7, 2021 -- TTC Oncology ("TTC" or the "Company") CEO and CMO Arek Dudek, MD, PhD, will be participating in the Biotech Showcase virtual conference occurring January 11-15, 2021. Dr. Dudek will be providing a Company overview and update on the Company's financing needs as well as TTC's lead product candidate, TTC-352.

To view the full announcement, including downloadable images, bios, and more, click here.

Key Takeaways:

• TTC Oncology CEO and CMO Arek Dudek, MD, PhD, will be participating in the Biotech Showcase virtual conference occurring January 11-15, 2021.
• Dr. Dudek will be providing a Company overview and update on the Company's financing needs as well as TTC's lead product candidate, TTC-352.
• TTC Oncology has completed a Phase I human clinical trial where TTC-352 was shown to have only minimal side effects. In several women participating in the trial, TTC-352 successfully treated breast tumors resistant to multiple lines of hormonal and chemotherapy treatments.

ABOUT BIOTECH SHOWCASE

Biotech Showcase is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place. Investors and biopharmaceutical executives from around the world gather in San Francisco during this bellwether week which sets the tone for the coming year. Now in its 13th year, this well-established, highly respected conference features multiple tracks of presenting companies, plenary sessions, workshops, networking, and an opportunity to schedule one-to-one meetings. Biotech Showcase is produced by Demy-Colton and EBD Group. Both organizations have a long history of producing high-quality programs that support the biotechnology and broader life sciences industry.

ABOUT TTC Oncology

TTC Oncology is an emerging biotechnology company founded in 2015. TTC Oncology's mission is to develop and bring to market a novel, small-molecule therapy, TTC-352, to address the unmet needs of breast cancer patients. TTC has a license from the University of Illinois at Chicago covering the therapy. They are seeking $15 million Series A investment to initiate and complete pivotal Phase II studies, and their goal is to complete studies in 36 months.

Contacts:

Klara Czobor

kczobor@ttconcology.com

Arek Dudek

adudek@ttconcology.com

Source: TTC Oncology

Distributed by: Reportable, Inc.